Showing 1941-1950 of 3223 results for "".
- Aldeyra Therapeutics to Modify Phase 3 TRANQUILITY -2 Trial in Dry Eye Disease After Missing Primary Endpointhttps://modernod.com/news/aldeyra-therapeutics-to-modify-phase-3-tranquility-trial-in-dry-eye-disease-after-missing-primary-endpoint/2480528/Aldeyra Therapeutics announced topline results from the Phase 3 TRANQUILITY trial of it investigational dry eye drug reproxalap. The primary endpoint of ocular redness was not met in TRANQUILITY, according to a company news release. However, statistical significance (P=0.0001) was
- Alimera Sciences Welcomes Ophthalmic Strategic Consultant Erin Parsons to Its Board of Directorshttps://modernod.com/news/alimera-sciences-welcomes-ophthalmic-strategic-consultant-erin-parsons-to-its-board-of-directors/2480483/Alimera Sciences announced the addition of Erin Parsons to its Board of Directors. Ms. Parsons has more than 20 years of experience working in the ophthalmic industry overseeing scientific strategy, medical communications, advocacy development, and peer-to-peer educational programs, muc
- Upneeq Wins 2021 Allure Best of Beauty Breakthrough Awardhttps://modernod.com/news/upneeq-wins-2021-allure-best-of-beauty-breakthrough-award/2480455/RVL Pharmaceutical’s Upneeq eye drops, which temporarily lift low-lying eyelids, was presented with a 2021 Best of Beauty Breakthrough Award by Allure Magazine.
- Alcon Unveils SMART Solutions Integration and Connectivity Platform at AAO 2021https://modernod.com/news/alcon-unveils-latest-evolution-of-cataract-integration-and-connectivity-at-aao-2021/2480414/At the American Academy of Ophthalmology (AAO) 2021 annual meeting in New Orleans, Alcon will feature its latest advancement in integrated and connected surgical technologi
- Alcon to Acquire Ivantis, Maker of the Hydrus Microstent for Surgical Glaucomahttps://modernod.com/news/alcon-to-acquire-ivantis-and-its-hydrus-microstent-for-surgical-glaucoma-strengthening-global-ophthalmology-portfolio/2480410/Alcon announced its intention to acquire Ivantis, developer and manufacturer of the Hydrus Microstent. The deal will strenghten Alcon's surgical glaucoma portfolio and allow it to enter the growing MIGS category. Under terms of the deal, Alcon will pay $475 million in upfr
- Alcon Inaugurates Company’s Largest European Eye Health Education and Training Center in Barcelonahttps://modernod.com/news/alcon-inaugurates-companys-largest-european-eye-health-education-and-training-centre-in-barcelona/2480404/Alcon officially opened the new Alcon Experience Center (AEC) in Barcelona, one of Europe's largest eye health education and training facilities, offering eye care professionals the opportunity to learn and gain hands-on experience with the latest innovations in ophthalmology and optometry. T
- Oyster Point Pharma Announces Patient Savings Program Where Eligible Patients Can Pay as Little as $0 for Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-patient-savings-program-where-eligible-patients-can-pay-as-little-as-0-for-tyrvaya-nasal-spray/2480401/Oyster Point Pharma announced it has launched a patient support program called TEAMTyrvaya where eligible1 patients can pay as little as $0 for Tyrvaya (varenicline solution) Nasal Spray 0.03 mg. The FDA, approved Tyrvaya Nasal Spray for the treatment of
- Aldeyra Therapeutics Announces Achievement of Primary Endpoint in Phase 2 Clinical Trial in Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-achievement-of-primary-endpoint-in-phase-2-clinical-trial-in-dry-eye-disease/2480392/Aldeyra Therapeutics announced achievement of the primary endpoint of ocular redness in a randomized, double-masked, vehicle-controlled phase 2 clinical trial in patients with dry eye disease. The clinical trial enrolled 158 patients: 80 patients were randomized to receive 0.25% re
- Allergan to Present New Data on Investigational AGN-190584 for the Treatment of Presbyopiahttps://modernod.com/news/allergan-to-present-new-data-on-investigational-agn-190584-for-the-treatment-of-presbyopia/2480377/Allergan announced that it will present new pooled analyses and post hoc results from the phase 3 trials of AGN-190584
- Alcon Celebrates World Sight Day 2021 in Communities Worldwide with Programs for Improved Access to Eye Carehttps://modernod.com/news/alcon-celebrates-world-sight-day-2021-in-communities-worldwide-with-programs-for-improved-access-to-eye-care/2480353/Alcon celebrates World Sight Day 2021 by taking action in communities across the globe to raise awareness of blindness and vision impairment as global public health issues. Celebrated annually in October, World Sig